PMID- 23023302
OWN - NLM
STAT- MEDLINE
DCOM- 20130522
LR  - 20211021
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 35
IP  - 11
DP  - 2012 Nov
TI  - Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a 
      potential ticagrelor-angiotensin receptor blocker interaction?
PG  - 647-8
LID - 10.1002/clc.22063 [doi]
AB  - Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the 
      Platelet Inhibition and Patient Outcomes (PLATO) trial. Because ticagrelor is the 
      first oral, reversible, twice-daily agent, sufficient information on drug 
      interactions is not available. Our objective was to ascertain the safety of 
      ticagrelor with other common medications. The US Food and Drug Administration 
      Complete Response Review indicates that renal adverse events (AEs) and renal 
      function AEs were higher in ticagrelor-treated patients who were concomitantly 
      treated with angiotensin receptor blockers (ARBs) >50% of study days compared to 
      ticagrelor-treated patients who did not receive ARBs >50% of study days. 
      Clopidogrel-treated patients showed a trend for an increase in adverse renal 
      events with ARB use. However, this was not as pronounced as that observed with 
      ticagrelor. Dyspnea was also significantly increased in patients on concomitant 
      ticagrelor-ARB compared to ticagrelor without concomitant ARB and clopidogrel 
      (21.4% vs 14.6% vs 9.9%, respectively) as well as angioedema (0.15% vs 0.09%). 
      Furthermore, in patients with a baseline estimated glomerular filtration rate 
      (eGFR) <30 mL/min, the risk of major bleeding, death, and renal failure was 
      increased in patients on ticagrelor compared to patients on clopidogrel. In 
      patients on ticagrelor, ARBs significantly increased the frequency of renal 
      related AEs, renal function AEs, and dyspnea. Moreover, in patients with a 
      baseline eGFR <30 mL/min, the risk of major bleeding, death, and renal failure 
      was increased in patients on ticagrelor compared to patients on clopidogrel.
CI  - (c) 2012 Wiley Periodicals, Inc.
FAU - DiNicolantonio, James J
AU  - DiNicolantonio JJ
FAU - Serebruany, Victor L
AU  - Serebruany VL
LA  - eng
PT  - Editorial
DEP - 20120928
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - Adenosine/adverse effects/*analogs & derivatives
MH  - Angiotensin II Type 1 Receptor Blockers/*adverse effects
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Dyspnea/*chemically induced
MH  - Glomerular Filtration Rate/drug effects
MH  - Hemorrhage/chemically induced
MH  - Humans
MH  - Kidney/*drug effects/physiopathology
MH  - Kidney Diseases/*chemically induced/physiopathology
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ticagrelor
MH  - Ticlopidine/adverse effects/analogs & derivatives
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC6652506
EDAT- 2012/10/02 06:00
MHDA- 2013/05/23 06:00
PMCR- 2012/09/28
CRDT- 2012/10/02 06:00
PHST- 2012/08/23 00:00 [received]
PHST- 2012/08/31 00:00 [revised]
PHST- 2012/10/02 06:00 [entrez]
PHST- 2012/10/02 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
PHST- 2012/09/28 00:00 [pmc-release]
AID - CLC22063 [pii]
AID - 10.1002/clc.22063 [doi]
PST - ppublish
SO  - Clin Cardiol. 2012 Nov;35(11):647-8. doi: 10.1002/clc.22063. Epub 2012 Sep 28.